CMDL offers comprehensive molecular testing for inherited diseases, enabling early
detection, confirmation, and risk assessment of genetic disorders across all age groups. Using advanced technologies such as PCR, real-time PCR, and sequencing-based
assays, we identify disease-causing mutations with high accuracy and sensitivity. Our
portfolio covers a wide range of conditions, including metabolic disorders, neuromuscular
diseases, hereditary cancers, and blood disorders. These tests support informed clinical
decisions, personalised treatment strategies, and family counselling. By delivering timely
and precise genetic insights, CMDL empowers clinicians to improve patient care, facilitate
preventive interventions, and guide families toward better health outcomes for future
generations.
